MarginsXMarginsX
Home › Markets › Health Care › TSHA

Taysha Gene Therapies Inc. (TSHA)

TSHA trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$4.06
-0.98% on the day
Market cap
$1.3B
Small cap
Revenue · 2025
$9.8M
+17.3% on 2024
Net income · 2025
-$109.0M
-1115.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/0001193125-26-115202-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerTSHA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2020
SEC CIK0001806310
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$9.8M
Net income-$109.0M
Operating income-$110.5M
Net margin-1115.3%
Operating margin-1130.6%
Revenue growth+17.3%
Cash$319.8M
Total assets$343.3M
P/E (computed)Net income was not positive
P/S (computed)135.4×

Warning signs

Cash runway
36.0 months
$422.8M cash at September 30, 2026
Share count, 1 year
+19.0%
2025-11-04 to 2026-11-12 · +74.4% over 3 years
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
-$6.7M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$422.8M cash; operating cash flow -$35.2M a quarter.Report 2026-09-30
Shares outstanding326,045,530 (2026-11-12); 273,919,373 a year earlier; 186,960,193 three years earlier.Cover page 2026-11-12
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-06-25
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, Chicago, Illinois, United StatesPCAOB Form AP 2026-03-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $6.7M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$39.1M-$32.9M$422.8M$47.3M$5.5M10-Q 2026-11-12
Q2 2026
2026-06-30
$0-$46.6M-$40.4M$455.4M$49.3M$5.5M10-Q 2026-08-11
Q1 2026
2026-03-31
$0-$42.4M-$40.9M$276.6M$49.0M$7.5M10-Q 2026-05-06
Q4 2025
2025-12-31
$5.5M-$27.9M-$26.7M$319.8M$50.1M$9.8M10-K 2026-03-19
Q3 2025
2025-09-30
$0-$32.7M-$24.2M$297.3M$50.9M$6.3M10-Q 2026-11-12
Q2 2025
2025-06-30
$2.0M-$26.9M-$20.2M$312.8M$41.1M$8.1M10-Q 2026-08-11
Q1 2025
2025-03-31
$2.3M-$21.5M-$22.0M$116.6M$42.5M$7.2M10-Q 2026-05-06
Q4 2024
2024-12-31
$2.0M-$18.8M-$18.3M$139.0M$43.9M$8.3M10-K 2026-03-19

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-06-25
Latest annual report10-K2026-03-19
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12
Latest proxyDEFA14A2026-04-22

Source: SEC EDGAR submissions feed, 404 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-5.3%
1 month+14.5%
3 months-31.6%
Year to date-25.5%
1 year+2.2%
From 52-week high-41.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
NVAXNovavax Inc.$8.06-5.45%$1.3B
LYCALycia Therapeutics Inc.$28.61-8.30%$1.5B
IMCRImmunocore Holdings plc$28.88-3.54%$1.5B
VORVor Biopharma Inc.$18.97-2.32%$1.2B
INBXInhibrx Biosciences Inc.$77.66-6.77%$1.1B
MESOMesoblast Limited$12.45-6.18%$1.6B
VIRVir Biotechnology Inc.$9.58-3.82%$1.6B
ALVOAlvotech$4.41+5.13%$1.7B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier